Skip to main content
SpringerLink
Log in

CYP2C19 genotyping worth it for H. pylori eradication in the US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

CYP2C19 genotyping worth it for H. pylori eradication in the US. Pharmacoecon. Outcomes News 443, 7 (2003). https://doi.org/10.1007/BF03277198

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03277198

Keywords

Search

Navigation